Photo: Tetra Images/Getty Images
In August, OpenAI CEO Sam Altman introduced the company's latest version of its advanced AI chatbot, GPT-5, while touting that the conversational tool should be used to help individuals understand their healthcare and make decisions along their journey.
Dr. Doug Fridsma, former chief science officer at the U.S. Office of National Coordinator for Health Information Technology and current chief medical informatics officer at Health Universe, joins HIMSSCast to discuss whether OpenAI's GPT-5 should be HIPAA compliant and/or regulated by the Food and Drug Administration.
"I really do think that consumers and patients require protections of their data, and I think a lot of the protections that we have right now are insufficient," Fridsma said.
"People don't realize that once they take their medical information and they voluntarily upload it to ChatGPT, the company can do anything they want with that information as long as it follows their Terms of Service that are listed in the click-through button that we all use."
To hear more about the critical balance between innovation and patient privacy, listen to the conversation with Doug Fridsma and Jessica Hagen, executive editor of MobiHealthNews.
Like what you hear? Subscribe to the podcast on Apple Podcasts, Spotify or Amazon Music.
Talking points:
- Implications of inputting personal health information in GPT-5.
- Receiving mental healthcare using conversational AI tools.
- Who do HIPAA regulations apply to?
- How Terms of Service can betray privacy protections.
- The government's ability to regulate AI services.
More about this episode:
OpenAI CEO Sam Altman says GPT-5 should be used for health
Q&A: Experts on GPT-5 and HIPAA compliance, part one
OpenAI introduces parental controls with mental health notifications
OpenAI unveils HealthBench to evaluate LLMs' safety in healthcare
Elon Musk consortium launches $97.4B takeover bid for OpenAI
Email the writer: jhagen@himm.org
